linjc16/ctgov huggingface dataset:
Endoscopic Partial Adenoidectomy Versus Total Adenoidectomy Regarding Rate of Recurrence and Relief of Symptoms

Study Overview
=================
Brief Summary
-----------------
Efficacy of partial adenoidectomy versus total adenoidectomy regarding rate of recurrence and relief of nasal obstruction.

Official Title
-----------------
Endoscopic Partial Adenoidectomy Versus Total Adenoidectomy Regarding Rate of Recurrence and Relief of Symptoms

Conditions
-----------------
Adenoidal Hypertrophy

Intervention / Treatment
-----------------
* Device: Endoscopic adenoidectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: .all patients with adenoid hypertrophy causing airway obstruction. Exclusion Criteria: 1. Chlidren known to have cleft palate ,submucous cleft palate or other medical problems causing velopharyngeal insufficiency. 2 . Systemic medical problems interfering with surgery. 3 . Refusal of parents to participate. 4. Craniofacial abnormalities. 5. Down syndrome.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Endoscopic total adenoidectomy<br> | Device: Endoscopic adenoidectomy<br>* Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .<br>|
| Active Comparator: Endoscopic partial adenoidectomy<br> | Device: Endoscopic adenoidectomy<br>* Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of partial adenoidectomy versus total adenoidectomy regarding rate of recurrence and relief of nasal obstruction. | 1. Relief of nasal obstruction while preserving the function of velopharyngeal valve and assessment of the recurrence rate. | 1 to 2 years . | 
| Incidence of recurrence using fibro-optic evaluation | Relief of nasal obstruction of posterior nasal chona using fibro-optic evaluation and assessment of recurrence rate using also questionnaires sheets to all parents. | 1 to 2 years . |
The Impact of the Social Cognitive Theory Based Educational Program on Women-headed Households' Social Health : A Field Trial

Study Overview
=================
Brief Summary
-----------------
The goal of this field trial was to compare in emale-headed households. The main question it aims to answer are: determine the effect of education based on social cognitive theory on the social health of female-headed households in female-headed households in Gonabad. Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks. The control group did not receive any training related to the intervention.

Official Title
-----------------
The Impact of the Social Cognitive Theory Based Educational Program on Women-headed Households' Social Health : A Field Trial

Conditions
-----------------
Social Behavior, Health Behavior

Intervention / Treatment
-----------------
* Other: test group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent to participate in the study, being the head of the household, age range from 20 to 64 years, ability to speak and listen, reading and writing literacy, access to a mobile phone with Android operating system to receive educational messages (access to the Internet and virtual networks) or Having access to a person who will help him in using virtual networks, not suffering from acute diseases and hospitalization during the intervention. Exclusion Criteria: Dissatisfaction to continue cooperation, not completing the questionnaire completely

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: test<br> | Other: test group<br>* Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks<br>|
| No Intervention: control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| social health | Social health is measured by the Keyes Social Health Questionnaire. This questionnaire | before | 
| social health | Social health is measured by the Keyes Social Health Questionnaire. This questionnaire includes 20 questions and examines 5 subscales of social prosperity, social solidarity, social cohesion, social acceptance and social participation.relationships with others | After 4 weeks |
A Retrospective Study of Early Postoperative Mobilization in the Recovery of Patients With Oral Head and Neck Tumors Who Underwent Flap Reconstruction

Study Overview
=================
Brief Summary
-----------------
All patients with head and neck cancers and osteomyelitis who underwent vascularized flap reconstruction at Shanghai Ninth People's Hospital (North Campus), Shanghai Jiao Tong University, from February 2020 to July 2021 were the object of a retrospective data collection.Depending on whether they had postoperative early mobilization, all patients were split into experimental and control groups.In the experimental group, patients were split into two groups based on the postoperative day(POD): the POD 0-1 group and the POD >1 group.Comparison and analysis were done on the difference in hospital days and post-operative complication rates between the two groups.

Official Title
-----------------
A Retrospective Study of Early Postoperative Mobilization in the Recovery of Patients With Oral Head and Neck Tumors Who Underwent Flap Reconstruction

Conditions
-----------------
Length of Hospital Stay

Intervention / Treatment
-----------------
* Behavioral: Early Mobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with head and neck diseases undergoing flap reconstruction and repair Patients with complete data preservation and consent Patients who follow medical advice during hospitalization Exclusion Criteria: Patients who survived less than 1 month after surgery Patients with other tumors before surgery 3, mental patients, audio-visual impairment or uncooperative patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early MobilizatioN<br> | Behavioral: Early Mobilization<br>* The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.<br>|
| conventional Mobilization<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospital stay after surgery | The time span between the end of surgery and hospital discharge is defined as the length of hospital stay after surgery. | February 2020 to July 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary infection rate | The pulmonary infection rate is calculated as the proportion of hospitalized patients who had pulmonary infections over all patients. | February 2020 to July 2021 | 
| deep vein thrombosis rate | The deep vein thrombosis rate is calculated as the proportion of hospitalized patients who had deep vein thrombosis over all patients. | February 2020 to July 2021 | 
| flap crisis rate | The flap crisis rate is calculated as the proportion of hospitalized patients who had flap crisis over all patients. | February 2020 to July 2021 |
Correlation of Clitoral Hood and Labia Minora Measurements and Female Genital Self Image Scale (FGSIS) Scores in Women

Study Overview
=================
Brief Summary
-----------------
To evaluate the relationship between women's labium minora and clitoral hood measurements and Female Genital Self Image Scale (FGSIS) scores.

Detailed Description
-----------------
The main purpose of our study is to measure the labium minora and clitoral hood in women who apply to our clinic with gynecological disorders, evaluate them with FGSIS (Female Genital Self Image Scale) scores, and look at the relationship between genital area perception and labium minora and clitoral hood dimensions.

Official Title
-----------------
Correlation of Clitoral Hood and Labia Minora Measurements and Female Genital Self Image Scale (FGSIS) Scores in Women

Conditions
-----------------
Vulva, Genital Diseases, Female

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who apply for outpatient gynecological control, are between the ages of 18-45, are sexually active, do not have additional endocrinological or malignant diseases, and are not pregnant or in menopause. Exclusion Criteria: Those who are not sexually active, have varying degrees of pelvic organ prolapse or urinary incontinence, have a malignancy, or have an endocrinological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of genital measurement with genital perception | Since the genital aesthetic trend is very popular today, it is important to understand the importance of labia minora and clitoral hood measurements in female genital perception. | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genital diseases, vulva
Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients

Study Overview
=================
Brief Summary
-----------------
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what research attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of pulmonary fibrosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary fibrosis patients.

Official Title
-----------------
A Comprehensive View of Patient Experiences of Individuals Participating in Pulmonary Fibrosis Clinical Study

Conditions
-----------------
Pulmonary Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 18 years of age Diagnosis of pulmonary fibrosis Ability to understand the study procedures, benefits and risks, and sign a written informed consent document. Exclusion Criteria: Enrolled in another research study Inability to provide written informed consent Women of childbearing potential without a negative pregnancy test; or women who are lactating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of pulmonary fibrosis patients who decide to participate in a clinical study |  | 3 months | 
| Rate of patients who remain in an pulmonary fibrosis clinical study to completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Fibrosis
Dynamic Web-Based Interventions to Improve Update of Preventive Health Recommendations in IBD

Study Overview
=================
Brief Summary
-----------------
To understand patient knowledge, attitudes, and beliefs around the uptake of vaccinations and malignancy screening through patient focus groups/qualitative interviews. To develop and pilot an interactive website that will provide customized recommendations for individual patients with IBD and direct them as relevant to five 60-90 second customized, animated videos (influenza, pneumococcal, and zoster vaccinations, bone health, and skin cancer screening). This content will be pilot-tested with patients to fine-tune the educational modules.

Official Title
-----------------
Dynamic Web-Based Interventions to Improve Update of Preventive Health Recommendations in IBD

Conditions
-----------------
IBD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: enrollees in the internet-based cohort IBD Partners, age 18 and older Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uptake of influenza vaccination | Uptake of influenza vaccination | Through study completion, no later than March 31, 2020 |
Prevalence of Oral Disorders in Children in ENT Pathologies

Study Overview
=================
Brief Summary
-----------------
Many children have eating and verbal oral disorders. Our research entitled: PREORA aims to study the prevalence of oral disorders presented in children consulting in ENT department for three months (n = 2000). This first study will be carried out by passing the MCH (Montreal Children's Hospital) feeding scale, a self-questionnaire completed by the parents, in order to assess the presence of disorders according to the parents and will allow us to present oral disorders (Score > 70).

Detailed Description
-----------------
Over a period of inclusion of 3 months, the doctors of the departement ONT, Robert Debré Hospital, will give written and oral information to the holders of parental authority and to the child at the beginning of the consultation. After a 15-minute reflection period (consultation time), if they agree to participate, parents will answer the doctor's questions and then complete the self-questionnaire.

Official Title
-----------------
Prevalence of Oral Disorders in Children Identified by Parents in the Context of ENT Pathologies

Conditions
-----------------
Eating Disorders, Language Disorders

Intervention / Treatment
-----------------
* Other: Auto-questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients consulting at ENT departement Robert Debré Hospital Age 0-17 years Parents and children informed and given their oral consent for the study and speaking french Exclusion Criteria: Refusal of parents/children to participate

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Auto-questionnaire MCH (Montreal Children's Hospital)<br>Auto-questionnaire MCH (Montreal Children's Hospital) | Other: Auto-questionnaire<br>* MCH (Montreal Children's Hospital) self questionnaire completed by the parents<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difficulty in feeding | MCH self questionnaire / HME score | 50 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eating disorders, Language disorders, Childhood
Genomics and Prognosis in GI Cancers

Study Overview
=================
Brief Summary
-----------------
This study aims to collect biospecimens and explore the correlation of genomics and prognosis in alimentary tract cancers.

Detailed Description
-----------------
In this study, the investigators will collect clinical specimens of alimentary tract cancers and perform DNA and RNA analysis to identify genetic alterations for the development of a comprehensive somatic mutation databases and investigate their potential correlation with clinical, radiological and pathological variables. The genomics study included but not limited to target gene panel sequencing, whole exome sequencing, whole genome sequencing, bulk RNA sequencing, single cell RNA sequencing and metagenomics.

Official Title
-----------------
Explore the Correlation of Genomics and Prognosis in Alimentary Tract Cancers

Conditions
-----------------
GI Cancer, Liver Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to sign the informed consent Age >= 20 Histology proved pancreatic cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, colorectal cancer Agree to provide tumor/normal tissue including but not limited to surgical specimen, biopsy, cytology specimen, bile, urine or stool Agree to receive blood sampling 20ml at first time and 10ml during each follow-up (total sampling amount no more than 30ml per month) Exclusion Criteria: Cannot cooperate with blood sampling

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who still survive at 1 year | 1 year overall survival rate | 1 year |
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare pharmacokinetics and safety of Irbesartan High and Amlodipine Fixed Dose Combination and coadministration of mono compounds in healthy adult volunteers

Official Title
-----------------
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan High/Amlodipine Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: Irbesartan High/Amlodipine FDC
* Drug: Irbesartan High
* Drug: Amlodipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are 19 years or older on screening Signed informed consent Healthy Volunteer Other inclusion applied Exclusion Criteria: Clinically relevant/significant findings as evaluated by the investigator Other exclusion applied

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Irbesartan High/Amlodipine Fixed dose combination<br>participants will receive one tablet of Irbesartan High/Amlodipine FDC in a crossover design | Drug: Irbesartan High/Amlodipine FDC<br>* Irbesartan High/Amlodipine FDC<br>|
| Experimental: Co-administration of Irbesartan High and Amlodipine<br>participants will receive one table each of Irbesartan High and Amlodipine in a crossover design | Drug: Irbesartan High<br>* Co-administration of Irbesartan High and Amlodipine<br>Drug: Amlodipine<br>* Co-administration of Irbesartan High and Amlodipine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCt of Irbesartan High and Amlodipine |  | 72 hours | 
| Cmax of Irbesartan High and Amlodipine |  | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf of Irbesartan High and Amlodipine |  | 72 hours | 
| AUCt/AUCinf of Irbesartan High and Amlodipine |  | 72 hours | 
| tmax of Irbesartan High and Amlodipine |  | 72 hours | 
| half-life of Irbesartan High and Amlodipine |  | 72 hours | 
| CL/F of Irbesartan High and Amlodipine |  | 72 hours | 
| Vz/F of Irbesartan High and Amlodipine |  | 72 hours |